0

0

0

0

0

0

0

0

0

healthcare | IST

Vidaza generic doing well, market share is increasing, says Shilpa Medicare

Mini

For entire interview, watch accompanying video.

The US Food and Drug Administration (US FDA) has given an all clear to Shilpa Medicare‘s formulation manufacturing facility at Jadcherla in Telangana, said Vishnukant Bhutada, MD of the company.
"We have done 32 filings from this plant including our customer filing", said Bhutada.
Talking about their Raichur unit, he said that the company had submitted response for Raichur unit observations to US FDA.
"Vidaza generic is doing well for the company and we are getting more market share from this molecule", he added.